The issued share capital of Medartis comprises 11‘730‘353 registered shares with a nominal value of CHF 0.20 per share. The company has offered 2‘994‘791 newly registered shares and thereby raising around CHF 142.6 Mio. in gross proceeds including all the over-allotment shares. At the opening price of CHF 54.00 per share, the placement volume corresponds (including all the over-allotment shares) to an amount of around CHF 161.7 Mio. The company has granted the Joint Global Coordinators of the offering an over-allotment option of 390‘625 newly registered shares.

Medartis Holding AG, headquartered in Basel, Switzerland, specializes in technically high-precision implants for the surgical fixation of bone fractures and osteotomies. Medartis develops and distributes titanium screws and plates, surgical instruments and system solutions for osteosynthesis in the area of the cranium and extremities. These ensure optimal and quick rehabilitation of the patient after a surgical procedure. Maintaining the highest quality standards, continuous further development and innovation as well as comprehensive services for doctors, OR personnel and patients have top priority. They are crucial for our long-term customer relationships and have formed the basis for sustainable success since the company was founded in 1997. Medartis is represented worldwide with 11 subsidiaries and a broad network of distributors. 


Any questions?

Please do not hesitate to contact Julian Chan.

 
About SIX
SIX serves the Swiss and Spanish financial centers and a broad international client base, offering stable and efficient infrastructure services. SIX operates stock exchanges and provides services in securities, financial information as well as the payments business. The company is owned by its users (about 120 financial institutions). With over 4,400 employees and a presence in 19 countries, SIX generated operating income of CHF 1.6 billion and EBITDA of CHF 443.7 million in 2024.
www.six-group.com